Search Results

You are looking at 71 - 80 of 272 items for :

  • "neutropenia" x
Clear All
Full access

Bradford R. Hirsch and Gary H. Lyman

, providing an excellent example of the strengths and weaknesses of the field. These agents are administered subcutaneously, starting 1 to 3 days after completion of cytotoxic therapy to reduce the severity and duration of neutropenia and the risk of febrile

Full access

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Megan S. Lim, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Suchitra Sundaram, Nina Wagner, Mary Dwyer and Hema Sundar

, for patients treated with ibrutinib and chlorambucil. Neutropenia (13%), pneumonia (12%), hypertension (8%), and anemia (7%) were the common grade ≥3 adverse events. Ibrutinib also improved PFS compared with chlorambucil in patients with high-risk CLL

Full access

William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer and Hema Sundar

statistically significant survival benefit compared with FC in patients aged <65 years (5-year OS, 80.9% and 69.2%, respectively; P =.002); corresponding 5-year OS rates were 73.9% and 61.6%, respectively ( P =.288). The incidence of prolonged neutropenia was

Full access

included Table 1. CDK 4/6 Inhibitors neutropenia, anemia, and fatigue. No cases of febrile neutropenia were observed. However, an increased rate of grade 3/4 infections and pulmonary embolism was seen in the palbociclib/letrozole arm (5% vs 0

Full access

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer and Hema Sundar

study. The most common treatment-related toxicities were neutropenia (grade 3/4; 20%) and infections (any grade; 53%), including those requiring intravenous antibiotics (27%). In a study of 358 patients with untreated HCL, cladribine resulted in a CR

Full access

Komal Jhaveri and Francisco J. Esteva

neutropenia were noted in 2 of 2 patients treated with 75 mg/m 2 of docetaxel and 1050 mg of pertuzumab every 3 weeks. Of 5 patients, 2 who received 100 mg/m 2 of docetaxel and 420 mg of pertuzumab (after a loading dose of 840 mg) every 3 weeks experienced

Full access

Alessandra Larocca and Antonio Palumbo

very good partial response (VGPR) were particularly higher with RD, as was 1-year PFS. However, this improvement did not translate into an overall survival advantage. The incidences of grade 3/4 neutropenia (21% vs. 5%) and thromboembolic events (24% vs

Full access

Gita Suneja

, vinblastine, and dacarbazine) is recommended for treating HL in people with HIV infection. However, dose reductions may be required for prolonged severe neutropenia. 7 In this population, growth factors may be required for those with a low CD4-positive T

Full access

Deborah A. f MD Kaseb Ahmed Omar g MD Cohen Lorenzo a PhD Bruera Eduardo a MD 9 2017 15 15 9 9 1111 1111 1120 1120 10.6004/jnccn.2017.0149 Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens

Full access

Neel K. Gupta and Charalambos Andreadis

adverse events were neutropenia (≈33%) and infusion-related reactions (≈20%). The study 16 showed that obinutuzumab/chlorambucil induced deeper and longer remissions than rituximab/chlorambucil, and the FDA subsequently approved the combination of